FINWIRES · TerminalLIVE
FINWIRES

Hong Kong Stocks Edge Higher as U.S.-Iran Talks Remain in Focus; Xuanzhu Biopharm Advances

-- Hong Kong equities gained on Wednesday as expectations of renewed U.S.-Iran dialogue eased geopolitical concerns.

The Hang Seng Index gained 75.00 points to end fractionally higher at 25,947.32, while the Hang Seng China Enterprises Index added 46.65 points, or 0.5%, to 8,718.26.

U.S. President Donald Trump said talks with Iran could resume within days after weekend negotiations broke down in Islamabad, Reuters reported.

Officials in Pakistan and Iran also indicated that discussions could restart.

Despite the optimism, the U.S. said its military had effectively halted all maritime trade to and from Iran, maintaining pressure on Tehran.

Oil prices extended declines for a second straight session as prospects of renewed talks reduced concerns over supply disruptions.

Still, refiners continued to seek alternative crude supplies, driving up premiums for barrels from regions such as the U.S. Gulf Coast and the North Sea.

In corporate news, Xuanzhu Biopharmaceutical (HKG:2575) closed over 10% higher after receiving approval in China to initiate a phase 3 trial for its Helicobacter pylori drug.

Related Articles

Asia

Shakti Pumps (India) Invests INR100 Million in EV Mobility Unit

Shakti Pumps (India) (NSE:SHAKTIPUMP, BOM:531431) said it has invested 100 million Indian rupees in its wholly owned subsidiary Shakti EV Mobility by subscribing to 10 million equity shares, according to a Tuesday filing to the Indian stock exchanges.Shares of the company rose 1% in Wednesday's trade.With this, Shakti Pumps' total investment in the EV mobility unit has increased to 650 million Indian rupees, the filing said.The investment is aimed at supporting business expansion of the subsidiary, it added.

$BOM:531431$NSE:SHAKTIPUMP
Asia

Challenger's Fiscal 2026 Q3 Update Missed Consensus Across Key Life Metrics, Jarden Says

Challenger's (ASX:CGF) fiscal 2026 third-quarter update missed consensus across key Life metrics, with FM outflows significantly worse than expected, driven by institutional equity mandate attrition in both Australian and global equities, according to a Tuesday note by Jarden.The firm's redemption of all CGFPC notes on May 25 simplifies the capital structure, reduces the AT1 coupon burden, and is earnings-per-share accretive.Jarden sees balanced risk/reward for Challenger in the future, with catalysts including capital management flexibility from the Australian Prudential Regulation Authority reform, as well as expanding retirement partnerships across superfunds.It lowered its fiscal 2026 sales forecast to reflect weaker institutional fixed-term sales, partially offset by higher retail annuity sales as partnerships come online.The investment firm retained its neutral rating on Challenger and raised the price target to AU$8.70 per share from AU$8.60 per share.

$ASX:CGF
Asia

Proya Cosmetics 2025 Profit Down 4%, Revenue Slips 2%

Proya Cosmetics (SHA:603605) posted 2025 attributable net profit of 1.50 billion yuan, down 3.5% from 1.55 billion yuan the previous year.Earnings per share slid to 3.80 yuan from 3.92 yuan, according to a Wednesday filing with the Shanghai bourse.Operating revenue declined 1.7% year over year to 10.6 billion yuan from 10.8 billion yuan.Shares of the cosmetics maker were up over 1% in recent trade.

$SHA:603605